Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Raises $66.9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Intrexon has raised $66.9 million, according to a document filed with the US Securities and Exchange Commission last week.

Based in Blacksburg, Va., the genetic engineering firm did not say how the funds will be used but said the offering was not made in connection with a business combination transaction such as a merger.

A total of 82 investors participated in the offering, though Intrexon did not identify them. The company, which had been called Genomatix, said the date of the first sale for the offering was Feb. 19, 2010.

A company spokesman declined to comment on the transaction.

In January 2010, Intrexon raised $25 million in equity financing.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.